ASB Consultores’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$267K Buy
+270
New +$274K 0.89% 30
2025
Q3
Sell
-490
Closed -$382K 87
2025
Q2
$382K Sell
490
-59
-11% -$45.8K 0.26% 69
2025
Q1
$453K Sell
549
-275
-33% -$229K 0.29% 48
2024
Q4
$636K Sell
824
-301
-27% -$249K 0.26% 59
2024
Q3
$997K Sell
1,125
-20
-2% -$18K 0.39% 37
2024
Q2
$1.04M Sell
1,145
-950
-45% -$760K 0.37% 30
2024
Q1
$1.63M Buy
2,095
+1,568
+298% +$1.12M 0.42% 29
2023
Q4
$307K Sell
527
-228
-30% -$133K 0.1% 69
2023
Q3
$406K Sell
755
-301
-29% -$155K 0.16% 63
2023
Q2
$495K Buy
1,056
+137
+15% +$57.5K 0.24% 76
2023
Q1
$316K Sell
919
-52
-5% -$17.5K 0.13% 124
2022
Q4
$355K Buy
971
+169
+21% +$59.9K 0.15% 105
2022
Q3
$259K Sell
802
-127
-14% -$40.2K 0.12% 134
2022
Q2
$301K Sell
929
-382
-29% -$115K 0.13% 108
2022
Q1
$375K Sell
1,311
-10
-0.8% -$2.57K 0.16% 119
2021
Q4
$365K Buy
+1,321
New +$335K 0.18% 123

Other funds holding LLY

ASB Consultores's LLY Position: Q1 2026 in Review

ASB Consultores opened a new position in Eli Lilly (LLY) in Q1 2026: 270 shares worth $267K. The stake represents 0.89% of the portfolio and ranks #30 among its holdings. This is a return to the name: ASB Consultores previously reported a position in LLY as recently as Q2 2025.

ASB Consultores first reported a position in LLY in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.63M in Q1 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • ASB Consultores held 270 shares of Eli Lilly worth $267K as of Q1 2026.
  • Eli Lilly was a new ASB Consultores position in Q1 2026.
  • Eli Lilly made up 0.89% of ASB Consultores's portfolio in Q1 2026, its #30 holding.
  • ASB Consultores first reported a position in Eli Lilly in Q4 2021 and has held it in 16 quarters since.
  • ASB Consultores's Eli Lilly position peaked at $1.63M in Q1 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on ASB Consultores's 13F filing for Q1 2026, filed 15 May 2026.